Clinical Trials Logo

Uveal Neoplasms clinical trials

View clinical trials related to Uveal Neoplasms.

Filter by:

NCT ID: NCT00398073 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Start date: October 2006
Phase: N/A
Study type: Interventional

RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells. PURPOSE: This randomized clinical trial is studying two different ways of giving vaccine therapy to compare how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.

NCT ID: NCT00334776 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: October 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.

NCT ID: NCT00329641 Completed - Iris Melanoma Clinical Trials

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works when given together with carboplatin and paclitaxel in treating patients with stage IV melanoma of the eye. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may help carboplatin and paclitaxel work better by making tumor cells more sensitive to the drugs. Sorafenib may also stop the growth of melanoma by blocking some of the enzymes needed for tumor cell growth and by blocking blood flow to the tumor. Giving sorafenib together with carboplatin and paclitaxel may kill more tumor cells.

NCT ID: NCT00313508 Completed - Melanoma (Skin) Clinical Trials

Dendritic Cell Vaccination During Lymphoid Reconstruction

Start date: February 2006
Phase: Phase 1
Study type: Interventional

This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms. The purpose of this study is to find out what side effects are caused in this study and whether Fludarabine with the dendritic cell vaccine (DC vaccine) can increase the ability of the immune system to recognize melanoma.

NCT ID: NCT00288041 Completed - Stage IV Melanoma Clinical Trials

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may help paclitaxel and carboplatin kill more tumor cells by making tumor cells more sensitive to these drugs

NCT ID: NCT00243061 Completed - Stage IV Melanoma Clinical Trials

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00238329 Completed - Melanoma (Skin) Clinical Trials

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing. PEG-interferon alfa-2b and thalidomide may also stop the growth of melanoma by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with thalidomide may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well giving PEG-interferon alfa-2b together with thalidomide works in treating patients with recurrent or metastatic melanoma.

NCT ID: NCT00089219 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Start date: July 2003
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating patients with stage IIIB, stage IIIC, or stage IV melanoma.

NCT ID: NCT00089206 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Start date: August 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

NCT ID: NCT00085189 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells